January 5, 2022 10:53 AM EST

Annexon shares fall 33% after patients drop out of Huntington's trial; Two Chinese biotechs net modest financing rounds

Annexon has some disappointing news, and it is evident at the Nasdaq.

Annexon, which went public back in 2020, had its share price $ANNX …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

An­nex­on shares fall 33% af­ter pa­tients drop out of Hunt­ing­ton's tri­al; Two Chi­nese biotechs net mod­est fi­nanc­ing rounds